CoChat

Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma

Open access

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Abstract

Background Ipilimumab can induce durable disease control and long-term survival in patients with metastatic melanoma. Identification of a biomarker that correlates with clinical benefit and potentially provides an early marker of response is an active area of research.Patients and methods Ipilimumab was available upon physician request for patients aged ≥16 years with stage III (unresectable) or IV cutaneous, ocular or mucosal melanoma, who had failed or did not tolerate previous treatments and had no other therapeutic option available. Patients received ipilimumab 3 mg/kg every 3 weeks for four doses. Tumour assessments were conducted at baseline, Week 12 and Week 24 using immune-related response criteria. Patients were monitored continuously for adverse events (AEs), including immune-related AEs. Candidate immunological markers were evaluated in peripheral blood and sera samples collected at baseline and Weeks 4, 7, 10 and 12.Results Among 95 patients treated with ipilimumab 3 mg/kg, the immune-related disease control rate at Week 24 was 38 %. With a median follow-up of 24 months, median overall survival was 9.6 months. Both disease control and survival were significantly associated with decreasing levels of lactate dehydrogenase, C-reactive protein and FoxP3/regulatory T cells, and increasing absolute lymphocyte count, between baseline and the end of dosing (Week 12).Conclusion Ipilimumab is a feasible treatment option for heavily pretreated patients with metastatic melanoma. Changes in some immunological markers between baseline and the fourth ipilimumab infusion appear to be associated with disease control and survival, but verification in prospective clinical trials is required.

Overview

Integrity signals

Registry

Crossref · 10.1007/s00262-014-1545-8

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 32 references

Cited by

Metadata

Authors
Simeone, E., Gentilcore, G., Giannarelli, D., Grimaldi, A. M., Caracò, C., Curvietto, M., Esposito, A., Paone, M., Palla, M., Cavalcanti, E., Sandomenico, F., Petrillo, A., Botti, G., Fulciniti, F., Palmieri, G., Queirolo, P., Marchetti, P., Ferraresi, V., Rinaldi, G., Pistillo, M. P., Ciliberto, G., Mozzillo, N., & Ascierto, P. A.
Affiliations
  • Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (IT)
  • Instituto Nazionale Tumori Regina Elena (IT)
  • National Research Council (IT)
  • Ospedale Policlinico San Martino (IT)
  • Istituto Dermopatico dell'Immacolata (IT)
  • Azienda Ospedaliera Universitaria Policlinico "Paolo Giaccone" di Palermo (IT)
Corresponding author
Ascierto, Paolo A.
Venue
Cancer Immunology, Immunotherapy
Published
2014-04-03
Volume
63
Issue
7
Pages
675-683
ISSN
  • 0340-7004 (ISSN-L)
  • 1432-0851
OpenAlex
W1965215390
Cited by
253
References
32
Citations by year
2025: 8 · 2024: 4 · 2023: 11 · 2022: 15 · 2021: 27 · 2020: 38 · 2019: 38 · 2018: 27 · 2017: 25 · 2016: 29 · 2015: 21 · 2014: 8
FWCI
13.34
Type
journal article
Language
en
Open access
Licence
www.springer.com/tdm (tdm)
Locations
  • Cancer Immunology Immunotherapy (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
  • UnissResearch (Università degli Studi di Sassari) (submittedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
ipilimumab, metastatic melanoma, immune checkpoint inhibitors, predictive biomarkers, immune-related adverse events, regulatory T cells, Foxp3, lactate dehydrogenase, C-reactive protein, lymphocyte count, disease control rate, overall survival, immune-related response criteria
MeSH terms
Ipilimumab, Adolescent, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Eye Neoplasms, Female, Humans, Male, Melanoma, Middle Aged, Skin Neoplasms, Survival Analysis, Treatment Outcome, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.